Abstract
The advent of highly active antiretroviral therapy (HAART) has significantly reduced the incidence of AIDS events, including AIDS-defining malignancies. Nevertheless, several cohort studies conducted in the post-HAART period have reported an increasing risk of non-AIDS-defining cancers (NADC).
Overall, the potential mechanisms leading to an increased risk of developing NADCs probably involve multiple known and unknown factors. In addition to ageing, chronic inflammation and ongoing immune system dysregulation, other contributing factors are co-infection with potentially oncogenic viruses (HBV, HCV, HPV, EBV) and high-risk behaviours such as tobacco smoking.
As a consequence of these risk factors, high standardized incidence ratios have been consistently reported, mainly in cohort studies regarding smoking-related cancers (lung cancer, but also pharyngeal and kidney cancer), due to the far more common cigarette smoking habit in the HIV-population. Also in the setting of infection-related malignancies, the high frequency of liver cancer, as a consequence of HBV and HCV co-infection is well known. Similarly, HPV infection accounts for the higher risk of anal cancer. On the same line, Hodgkin lymphoma is more frequent in the HIV population, due to the dysregulation and proliferation of EBV-infected lymphocytes.
Several studies addressed the direct relationship between immunosuppression and cancer progression, showing that subjects with HIV infection experience higher cancer-specific mortality, as compared to the general population, independently of cancer stage or cancer treatment.
In the HIV population, for many NADCs, the prognosis is still worse as compared to the general population. However, an improvement has been reported over the last decades, mainly thanks to more available and adequate treatment chances.
Keywords: HIV, AIDS, NADCs, cancer incidence, cancer mortality, HAART.
Graphical Abstract
[1]
Fabrice B, Charlotte L, Thierry M. Malignancy-Related Causes of Death in Human Immunodeficiency Virus–Infected Patients in the Era of Highly Active Antiretroviral Therapy. Cancer 2004; 101: 317-24.
[2]
Costagliola D, May M. Survival in individuals living with HIV. Curr Opin HIV AIDS 2016; 11: 451-4.
[3]
Wong C, Gange SJ, Moore RD, et al. Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clin Infect Dis 2018; 66: 1230-8.
[4]
Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43(1): 27-34.
[5]
Vandentorren S, Mercie´ P, Marimoutou C, et al. Trends in causes of death in the Aquitaine cohort of HIV-infected patients, 1995-1997. Eur J Epidemiol 2001; 17: 7-10.
[6]
Deeken JF, Tjen-A-Looi A, Rudek MA. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012; 55: 1228-35.
[7]
Brugnaro P, Morelli E, Cattelan F. Non-acquired immunodeficiency syndrome defining malignancies among human immunodeficiency virus positive subjects: Epidemiology and outcome after two decades of HAART era. World J Virol 2015; 4(3): 209-18.
[8]
Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98: 2339-44.
[9]
Engels EA, Yanik EL, Wheeler W, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis 2017; 65(4): 636-43.
[10]
Hessol NA, Ma D, Scheer S, et al. Changing temporal trends in non-AIDS cancer mortality among people diagnosed with AIDS: San Francisco, California, 1996-2013. Cancer Epidemiol 2018; 52: 20-7.
[11]
Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration. Lancet 2014; 384: 241-8.
[12]
Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. Lancet HIV 2018; 5: e647-55.
[13]
Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
[14]
Franzetti M, Adorni F, Parravicini C, et al. Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: A single-institution retrospective study before and after the introduction of HAART. J Acquir Immune Defic Syndr 2013; 62: 414-20.
[15]
Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23: 2337-45.
[16]
Bruyand M, Le Marec F, Lavole A, et al. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study. AIDS 2015; 29: 1105-9.
[17]
Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV infected individuals. Acquir Immune Defic Syndr 2009; 52: 611-22.
[18]
Vaccher E, Serraino D, Carbone A, De Paoli P. The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care. Oncologist 2014; 19(8): 860-7.
[19]
Cobucci RN, Lima PH, de Souza PC, et al. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. J Infect Public Health 2015; 8: 1-10.
[20]
Hessol NA, Seaberg EC, Preston-Martin S, et al. Cancer risk among participants in the women’s interagency HIV study. J Acquir Immune Defic Syndr 2004; 36: 978-85.
[21]
Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010; 116: 5507-16.
[22]
Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23: 41-50.
[23]
Dal Maso L, Polesel J, Serraino D, et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009; 100: 840-7.
[24]
IRC Working Group A Review of Human Carcinogens: Biological Agents Vol 100B. Lyon, France: International Agency for Research on Cancer 2012.
[25]
Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2001; 103: 753-62.
[26]
Chiu CG, Smith D, Salters KA, et al. Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development. BMC Cancer 2017; 17: 270.
[27]
Raffetti E, Albini L, Gotti D, et al. Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study. BMC Public Health 2015; 15: 235.
[28]
Fink VI, Shepherd BE, Cesar C, et al. Cancer in HIV-infected persons from the Caribbean, Central and South America. J Acquir Immune Defic Syndr 2011; 56: 467-73.
[29]
Tanaka LF, Latorre MDRD, Gutierrez EB, et al. Trends in the incidence of AIDS-defining and non-AIDS-defining cancers in people living with AIDS: a population-based study from São Paulo, Brazil. Int J STD AIDS 2017; 28: 1190-8.
[30]
Dubrow R, Silverberg MJ, Park LS, et al. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 2012; 24: 506-16.
[31]
Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-36.
[32]
Prosperi MC, Cozzi-Lepri A, Castagna A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 2010; 50: 1316-21.
[33]
Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24: 1383-8.
[34]
Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116: 5306-15.
[35]
Frisch M, Biggar RJ, Engels EA, et al. AIDS-Cancer Match Registry Study Group.Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736-45.
[36]
Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-32.
[37]
Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52: 203-8.
[38]
Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011; 52: 1458-65.
[39]
Borges AH, Dubrow R, Silverberg MJ. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier cART will alter this risk. Curr Opin HIV AIDS 2014; 9: 34-40.
[40]
Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2551-9.
[41]
Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 27(373): 808-22.
[42]
Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.
[43]
Borges ÁH, Neuhaus J, Babiker AG, et al. Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection. Clin Infect Dis 2016; 63: 1668-76.
[44]
Bruyand M, Thiébaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009; 49: 1109-16.
[45]
Clark E, Nava B, Caputi M. Tat is a multifunctional viral protein that modulates cellular gene expression and functions. Oncotarget 2017; 8: 27569-81.
[46]
Caccuri F, Marsico S, Fiorentini S. HIV-1 Matrix Protein p17 and its Receptors. Curr Drug Targets 2016; 17: 23-32.
[47]
Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol 2009; 10: 1152-9.
[48]
Krishnan S, Schouten JT, Jacobson DL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology 2011; 80: 42-9.
[49]
Hecht M, Harrer T, Büttner M, et al. Cytotoxic effect of Efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS 2013; 27: 2031-40.
[50]
National Toxicology Program.Toxicology and carcinogenesis studies of mixtures of 3′-azido-3′-deoxythymidine (AZT), lamivudine (3TC), nevirapine (NVP), and nelfinavir mesylate (NFV) (Cas Nos 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (transplacental exposure studies). Natl Toxicol Program Tech Rep Ser 2013; 569: 1-212.
[51]
Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-90.
[52]
Chao C, Leyden WA, Xu L, et al. Exposure to antiretroviral therapy and risk of cancer in HIV infected persons. AIDS 2012; 26: 2223-31.
[53]
Bruyand M, Ryom L, Shepherd L, et al. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D: A: D study. J Acquir Immune Defic Syndr 2015; 68: 568-77.
[54]
Varadarajan J, McWilliams MJ, Hughes SH. Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. Proc Natl Acad Sci USA 2013; 110: 14747-52.
[55]
Cozzi-Lepri A, Zangerle R, Machala L, et al. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Med 2018; 19: 102-17.
[56]
Borges ÁH. Combination antiretroviral therapy and cancer risk. Curr Opin HIV AIDS 2017; 12: 12-9.
[57]
Boyd A, Lacombe K, Girard PM. An improved understanding of severe liver morbidity in HIV-infected individuals. AIDS 2016; 30: 1843-5.
[58]
Babu CK, Suwansrinon K, Bren GD, Badley AD, Rizza SA. HIV induces TRAIL sensitivity in hepatocytes. PLoS One 2009; 4: e4623.
[59]
Barreiro P, Labarga P, de Mendoza C, et al. High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy. Antivir Ther 2016; 21: 489-94.
[60]
Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108: 3786-91.
[61]
Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007; 38: 1293-304.
[62]
Watson AJ, Smith BB, Whitehead MR, et al. Malignant progression of anal intra-epithelial neoplasia. Adv J Surg 2006; 76: 715-7.
[63]
Méndez-Martínez R, Rivera-Martínez NE, Crabtree-Ramírez B. Multiple human papillomavirus infections are highly prevalent in the anal canal of human immunodeficiency virus-positive men who have sex with men. BMC Infect Dis 2014; 14: 671.
[64]
Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high risk HIV-negative women. J Infect Dis 2001; 183(3): 383-91.
[65]
Guidry JT, Scott RS. The interaction between human papillomavirus and other viruses. Virus Res 2017; 231: 139-47.
[66]
Ceccarelli M, Rullo EV, Facciolà A, et al. Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review. Oncotarget 2018; 9(24): 17171-80.
[67]
Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004; 37: 1563-5.
[68]
Wilkin TJ, Chen H, Cespedes MS, et al. Placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS clinical trials group protocol A5298. Clin Infect Dis 2018; 67(9): 1339-46.
[69]
Tesoriero JM, Gieryic SM, Carrascal A, et al. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010; 14: 824-35.
[70]
Frazier EL, Sutton MY, Brooks JT, et al. Trends in cigarette smoking among adults with HIV compared with the general adult population, United States - 2009-2014. Prev Med 2018; 111: 231-4.
[71]
Beachler DC, Weber KM, Margolick JB, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev 2012; 21: 122-33.
[72]
Achhra AC, Sabin C, Ryom L, et al. Body mass index and the risk of serious non-AIDS events and all-cause mortality in treated HIV-positive individuals: D: A: D Cohort Analysis. J Acquir Immune Defic Syndr 2018; 78(5): 579-88.
[73]
Shiels MS, Althoff KN, Pfeiffer RM. HIV infection, immunosuppression, and age at diagnosis of non-AIDS-defining cancers. Clin Infect Dis 2017; 64: 468-75.
[74]
Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21: 1957-63.
[75]
Borges AH, Silverberg MJ, Wentworth D, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 2013; 27: 1433-41.
[76]
Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013; 56: 1471-9.
[77]
Borges ÁH, Neuhaus J, Sharma S, et al. The effect of interrupted/deferred antiretroviral therapy on disease risk: A SMART and START combined analysis. J Infect Dis 2019; 219: 254-63.
[78]
Marcus JL, Chao C, Leyden WA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev 2015; 24: 1167-73.
[79]
Maso LD, Suligoi B, Franceschi S, et al. Survival after cancer in Italian persons with AIDS, 1986-2005: a population-based estimation. J Acquir Immune Defic Syndr 2014; 66: 428-35.
[80]
Acherbach CJ, Cole SR, Kitahara MM, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011; 25: 691-700.
[81]
May MT, Hogg RS, Justice AC, et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol 2012; 41: 1807-20.
[82]
Suneja G, Shiels MS, Angulo R, et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol 2014; 32: 2344-50.
[83]
Suneja G, Boyer M, Yehia BR, et al. Cancer treatment in patients with HIV infection and non-AIDS-defining cancers: a survey of US oncologists. J Oncol Pract 2015; 11: e380-7.
[84]
Tanaka LF, Latorre MDRDO, Gutierrez EB, et al. Cancer survival in people with AIDS: A population-based study from São Paulo, Brazil. Int J Cancer 2018; 142: 524-33.
[85]
Campbell JA, Soliman AS, Kahesa C, et al. Changing patterns of lung, liver, and head and neck non-AIDS-defining cancers relative to HIV status in Tanzania between 2002-2014. Infect Agent Cancer 2016; 11: 58.
[86]
Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early and late-HAART periods: The Swiss HIV Cohort Study. Br J Cancer 2010; 103: 416-22.
[87]
Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 2010; 51: 957-62.
[88]
Mani D, Haigentz M, Aboulafia DM. Lung cancer in HIV Infection. Clin Lung Cancer 2012; 13: 6-13.
[89]
D’Jaen GA, Pantanowitz L, Bower M, et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010; 11: 396-404.
[90]
Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000; 11: 753-9.
[91]
Polesel J, Franceschi S, Suligoi B, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer 2010; 127: 1437-45.
[92]
Hleyhel M, Bouvier AM, Belot A, et al. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS 2014; 28: 2109-18.
[93]
Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. J Clin Oncol 2015; 33: 2376-83.
[94]
Suneja G, Shiels MS, Melville SK, et al. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 2013; 27: 459-68.
[95]
Makinson A, Tenon JC, Eymard-Duvernay S, et al. Human immunodeficiency virus infection and non-small cell lung cancer: Survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol 2011; 6: 1022-9.
[96]
Pakkala S, Chen Z, Rimland D, et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012; 118: 164-72.
[97]
Bearz A, Vaccher E, Martellotta F, et al. Lung cancer in HIV positive patients: the GICAT experience. Eur Rev Med Pharmaco 2014; 18: 500-8.
[98]
Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-54.
[99]
Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017; 4: 495-504.
[100]
Sacchi P, Cima S, Corbella M, et al. Liver Fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and HIV/HCV co-infection. Dig Liver Dis 2015; 47: 218-25.
[101]
Marcon PDS, Tovo CV, Kliemann DA, et al. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study. World J Gastroenterol 2018; 24: 613-22.
[102]
Zucchetto A, Suligoi B, De Paoli A, et al. Excess mortality for non-AIDS-defining cancers among people with AIDS. Clin Infect Dis 2010; 51: 1099-101.
[103]
Berretta M, Garlassi E, Cacopardo B, et al. Hepatocellular carcinoma in HIV-infected patients: Check early, treat hard. Oncologist 2011; 16: 1258-69.
[104]
Shaffer AA, Durand CM. Solid organ transplantation for HIV-infected individuals. Curr Treat Options Infect Dis 2018; 10: 107-20.
[105]
Kreuter A, Potthoff A, Brockmeyer NH, et al. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol 2010; 162: 1269-77.
[106]
Tong WW, Hillman RJ, Kelleher AD, et al. Anal intraepithelial neoplasia and squamous cell carcinoma in HIV-infected adults. HIV Med 2014; 15: 65-76.
[107]
Hoots BE, Palefsky J, Pimenta J, et al. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124: 2375-83.
[108]
Bertisch B, Franceschi S, Lise M, et al. Risk factors for anal cancer in persons infected with HIV: A nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol 2013; 178: 877-84.
[109]
Duncan KC, Chan KJ, Chiu CG, et al. HAART slows progression to anal cancer in HIVinfected MSM. AIDS 2015; 29: 305-11.
[110]
Oehler-J¨anne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: A multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26: 2550-7.
[111]
White EC, Khodayari B, Erickson KT, et al. Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-negative patients with squamous cell carcinoma of the anal canal. Am J Clin Oncol 2017; 40: 386-92.
[112]
Chiao EY, Giordano TP, Richardson P, et al. Human immunodeficiency virus-associated squamous cell cancer of the anus: Epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008; 26: 474-9.
[113]
Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS 2014; 28(6): 881-90.
[114]
Carbone A, Gloghini A. Epstein Barr Virus-Associated Hodgkin Lymphoma. Cancers 2018; 10(6): 163.
[115]
Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009; 113: 5737-42.
[116]
Kowalkowski MA, Mims MP, Amiran ES. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS One 2013; 8: e77409.
[117]
Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colonystimulating factor in HIV-infected patients with newly diagnosed Hodgkin’s disease: A prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24: 444-50.
[118]
Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 2012; 30: 4111-6.
[119]
Sorigué M, García O, Tapia G, et al. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma. AIDS 2017; 31: 1445-9.
[120]
Corona G, Vaccher E, Spina M, et al. Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin’s lymphoma. AIDS 2013; 27: 1033-5.
[121]
Crum-Cianflone N, Hullsiek KH, Satter E, et al. Cutaneous malignancies among HIV-infected persons. Arch Intern Med 2009; 169: 1130-8.
[122]
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-91.
[123]
Sutton L, Guénel P, Tanguy ML, et al. Acute myeloid leukaemia in human immunodeficiency virus-infected adults: epidemiology, treatment feasibility and outcome. Br J Haematol 2001; 112: 900-8.
[124]
Evans MW, Sung AD, Gojo I, et al. Risk assessment in human immunodeficiency virus associated acute myeloid leukemia. Leuk Lymphoma 2012; 53: 660-4.
[125]
Goedert JJ, Schairer C, McNeel TS, et al. Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer 2006; 95: 642-8.
[126]
Nagata N, Nishijima T, Niikura R, et al. Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study. BMC Cancer 2018; 18: 1066.
[127]
Shiels MS, Islam JY, Rosenberg PS, et al. Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030. Ann Intern Med 2018; 168: 866-73.
[128]
Palefsky JM. Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era. Curr Opin HIV AIDS 2017; 12: 26-30.
[129]
Dalla Pria A, Merchant S, Bower M. Oncological challenges for an ageing population living with HIV. AIDS 2017; 31: S185-9.
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
An Epidemiological Update on COVID -19
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-infective Agents
Coronavirus Disease-19 (COVID-19): A Perspective of New Scenario
Article Metrics
92
17